Invesco Pharmaceuticals ETF is a ETF series of Invesco Exchange-Traded Fund Trust (series S000003031). Net assets $333.1M as of 2026-04-30. Index fund.
Showing 15 of 34 holdings by value.
| Holding | Ticker | Value | % of fund |
|---|---|---|---|
| Invesco Private Prime Fund | — | $40.2M | 1206.29% |
| Pfizer Inc. | — | $17.4M | 521.34% |
| Johnson & Johnson | — | $16.5M | 494.74% |
| AbbVie Inc. | — | $16.3M | 490.19% |
| Amgen Inc. | — | $16.0M | 479.22% |
| Eli Lilly and Co. | — | $15.8M | 475.70% |
| Gilead Sciences, Inc. | — | $15.6M | 469.61% |
| Merck & Co., Inc. | — | $15.5M | 466.83% |
| Invesco Private Government Fund | — | $15.5M | 464.50% |
| Abbott Laboratories | — | $14.0M | 419.95% |
| Travere Therapeutics, Inc. | — | $13.3M | 400.30% |
| Corcept Therapeutics Inc. | — | $12.5M | 374.24% |
| Ligand Pharmaceuticals Inc. | — | $11.9M | 356.15% |
| United Therapeutics Corp. | — | $11.8M | 354.12% |
| Liquidia Corp. | — | $11.4M | 342.79% |
| Report date | Net assets |
|---|---|
| 2026-04-30 | $333.1M |
| 2026-01-31 | $402.1M |
| 2025-10-31 | $276.9M |
| 2025-07-31 | $232.2M |
| 2025-04-30 | $243.7M |
| 2025-01-31 | $265.1M |
| 2024-10-31 | $280.8M |
| 2024-07-31 | $284.9M |